Nuveen Asset Management LLC acquired a new stake in Global Blood Therapeutics Inc (NASDAQ:GBT) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 219,203 shares of the company’s stock, valued at approximately $11,530,000.
Several other large investors have also made changes to their positions in GBT. Steward Partners Investment Advisory LLC acquired a new position in shares of Global Blood Therapeutics during the second quarter worth about $27,000. Captrust Financial Advisors acquired a new position in shares of Global Blood Therapeutics during the second quarter worth about $42,000. NumerixS Investment Technologies Inc acquired a new position in shares of Global Blood Therapeutics during the second quarter worth about $63,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Global Blood Therapeutics by 17.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,265 shares of the company’s stock worth $172,000 after purchasing an additional 482 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Global Blood Therapeutics by 3,272.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,440 shares of the company’s stock worth $181,000 after purchasing an additional 3,338 shares in the last quarter. 97.99% of the stock is owned by institutional investors and hedge funds.
NASDAQ:GBT opened at $46.53 on Friday. The company has a current ratio of 16.79, a quick ratio of 16.79 and a debt-to-equity ratio of 0.03. Global Blood Therapeutics Inc has a one year low of $30.15 and a one year high of $64.94. The business’s 50-day simple moving average is $49.66 and its 200 day simple moving average is $54.28.
Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by ($0.05). During the same period last year, the business posted ($0.78) earnings per share. Sell-side analysts forecast that Global Blood Therapeutics Inc will post -4 earnings per share for the current year.
A number of research analysts have commented on GBT shares. BidaskClub cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 1st. Cantor Fitzgerald set a $110.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Friday, June 14th. William Blair restated a “buy” rating on shares of Global Blood Therapeutics in a research note on Tuesday. Wells Fargo & Co boosted their price target on Global Blood Therapeutics from $96.00 to $104.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Morgan Stanley set a $60.00 price target on Global Blood Therapeutics and gave the stock a “hold” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $90.42.
In related news, insider Lesley Ann Calhoun sold 2,765 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $54.36, for a total value of $150,305.40. Following the completion of the sale, the insider now directly owns 887 shares of the company’s stock, valued at $48,217.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Deval L. Patrick sold 5,357 shares of the business’s stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $45.05, for a total value of $241,332.85. Following the completion of the sale, the director now directly owns 5,357 shares of the company’s stock, valued at $241,332.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,371 shares of company stock valued at $549,865. 4.30% of the stock is owned by corporate insiders.
Global Blood Therapeutics Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Recommended Story: Moving Average – How it Helps Investors in Stock Selection
Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.